CAMP4 Therapeutics Corporation (CAMP) Price & Analysis

Compare

120 Followers

CAMP Stock Chart & Stats

$5.94

-$0.13(-2.84%)

At close: Jan 08 4:00 PM EST

$5.94

-$0.13(-2.84%)

Day’s Range― - ―

52-Week Range$1.31 - $7.50

Previous Close$4.45

Volume38.22K

Average Volume (3M)1.59M

Market Cap

$308.17M

Enterprise Value-$8.43M

Total Cash (Recent Filing)$75.25M

Total Debt (Recent Filing)$6.35M

Price to Earnings (P/E)―

Beta1.98

Next Earnings

Mar 26, 2026

EPS Estimate

-0.3

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.55

Shares Outstanding51,881,134

10 Day Avg. Volume141,089

30 Day Avg. Volume1,592,597

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)1.61

Price to Sales (P/S)156.16

P/FCF Ratio-2.21

Enterprise Value/Market Cap-0.03

Enterprise Value/Revenue-2.22

Enterprise Value/Gross Profit-2.49

Enterprise Value/Ebitda0.16

Forecast

1Y Price Target

$9.00

Price Target Upside51.52% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Capital And FundingThe company has raised $50M in a private placement, providing a financial runway into 2027 and demonstrating investor confidence.

Financial MilestonesCAMP4 will be eligible for up to $440M in development and commercial milestone payments as well as tiered royalties on annual net sales of licensed products.

Strategic PartnershipsThe strategic collaboration with GSK provides strong validation for CAMP4's regulatory RNA-targeting technology platform.

Bears Say

CAMP4 Therapeutics Corporation News

Camp4 Therapeutics prices 5M shares at $6.00 in underwritten public offering

CAMP4 Therapeutics (CAMP) announced the pricing of its underwritten offering of 5,000,000 shares of its common stock at...

7d ago

CAMP

Camp4 Therapeutics 5M share Secondary priced at $6.00

Leerink acted as sole book running manager for the offering. Published first on TheFly – the ultimate source...

7d ago

CAMP

Camp4 Therapeutics, GSK enter strategic collaboration

CAMP4 Therapeutics (CAMP) has entered into a strategic research, collaboration and license agreement with GSK (GSK) to identify...

7d ago

GSK

CAMP

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

13d ago

CAMP

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

14d ago

CAMP

IBIO

CAMP4 Therapeutics Restructures Leases and Expands Facilities

An announcement from CAMP4 Therapeutics Corporation ( ($CAMP) ) is now available. On December 22, 2025, CAMP4 Therapeutics...

2d ago

CAMP

CAMP4 Therapeutics: GSK Collaboration and Strengthened Funding Base De-Risk CMP-002 Development and Support Buy Rating

Analyst Yun Zhong of Wedbush maintained a Buy rating on CAMP4 Therapeutics Corporation, retaining the price target of...

6d ago

CAMP

CAMP4 Therapeutics Announces $28 Million Common Stock Offering

CAMP4 Therapeutics Corporation ( ($CAMP) ) has shared an announcement. On December 18, 2025, CAMP4 Therapeutics Corporation entered...

7d ago

CAMP

External Validation and Strengthened Balance Sheet Underpin Buy Rating on CAMP4 Therapeutics

William Blair analyst Myles Minter has reiterated their bullish stance on CAMP stock, giving a Buy rating on...

7d ago

CAMP

CAMP4, GSK form RNA therapeutics collaboration agreement

CAMP4 Therapeutics Corporation ( ($CAMP) ) has provided an announcement. On December 17, 2025, CAMP4 Therapeutics entered into...

7d ago

CAMP

CAMP Earnings this Week: How Will it Perform?

CAMP4 Therapeutics Corporation (CAMP) is scheduled to report 3rd quarter earnings on 11/20/2025, after the market closes. Regarding...

1M ago

CAMP

Strategic Focus and Financial Strength Drive Buy Rating for CAMP4 Therapeutics

Analyst Yun Zhong of Wedbush reiterated a Buy rating on CAMP4 Therapeutics Corporation, retaining the price target of...

2M ago

CAMP

Camp4 Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $7 price target Camp4 is...

3M ago

CAMP

Camp4 Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $7 price target Published first...

3M ago

CAMP

CAMP FAQ

What was CAMP4 Therapeutics Corporation’s price range in the past 12 months?

CAMP4 Therapeutics Corporation lowest stock price was $1.30 and its highest was $7.50 in the past 12 months.

What is CAMP4 Therapeutics Corporation’s market cap?

CAMP4 Therapeutics Corporation’s market cap is $308.17M.

When is CAMP4 Therapeutics Corporation’s upcoming earnings report date?

CAMP4 Therapeutics Corporation’s upcoming earnings report date is Mar 26, 2026 which is in 91 days.

How were CAMP4 Therapeutics Corporation’s earnings last quarter?

CAMP4 Therapeutics Corporation released its earnings results on Nov 20, 2025. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.478 by -$0.072.

Is CAMP4 Therapeutics Corporation overvalued?

According to Wall Street analysts CAMP4 Therapeutics Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CAMP4 Therapeutics Corporation pay dividends?

CAMP4 Therapeutics Corporation does not currently pay dividends.

What is CAMP4 Therapeutics Corporation’s EPS estimate?

CAMP4 Therapeutics Corporation’s EPS estimate is -0.3.

How many shares outstanding does CAMP4 Therapeutics Corporation have?

CAMP4 Therapeutics Corporation has 51,881,134 shares outstanding.

What happened to CAMP4 Therapeutics Corporation’s price movement after its last earnings report?

CAMP4 Therapeutics Corporation reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.478. Following the earnings report the stock price went down -17.379%.

Which hedge fund is a major shareholder of CAMP4 Therapeutics Corporation?

Currently, no hedge funds are holding shares in CAMP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

CAMP4 Therapeutics Corporation Stock Smart Score

Underperform

Company Description

CAMP4 Therapeutics Corporation

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CAMP4 Therapeutics Corporation (CAMP) Earnings & Revenues

Historic Earnings Reports

CAMP Stock 12 Month Forecast

Average Price Target

$9.00

▲(51.52% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.24,3.913846153846154,4.587692307692308,5.261538461538462,5.935384615384615,6.60923076923077,7.283076923076924,7.956923076923077,8.630769230769232,9.304615384615385,9.978461538461538,10.652307692307692,11.326153846153847,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.24,3.683076923076923,4.126153846153846,4.569230769230769,5.012307692307692,5.455384615384615,5.898461538461539,6.341538461538462,6.7846153846153845,7.227692307692307,7.67076923076923,8.113846153846154,8.556923076923077,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.24,3.5292307692307694,3.8184615384615386,4.107692307692308,4.396923076923077,4.686153846153847,4.975384615384616,5.264615384615385,5.553846153846154,5.843076923076923,6.132307692307693,6.421538461538462,6.710769230769231,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.75,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.75,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.05,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.24,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >